NVS
Novartis AG$148.40
LiveJun 04, 2026
Market cap
$283.16B
52w range
112.34 – 170.46
P / E
—
EPS
—
Volume
2.49M
Revenue · FY
—
Explain this page
Arphra AIPlain-English read on Novartis AG’s valuationAI Issuer Brief
Arphra AILoading cached brief…
Peers
No peer list available for NVS.
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.30% | -2.27% | +1.99% | -7.83% | +12.29% | +7.64% | +25.99% | +57.82% | +74.90% | +118.14% | +843.42% |
Aftermarket
LiveLast trade
$148.91
487 sh
Bid
$147.04
700 sh
Ask
$155.00
700 sh
Spread
$7.960
Sector & industry today
LiveSectors
- Technology+2.24%
- Utilities+1.75%
- Industrials+1.45%
- Healthcare+1.23%
- Real Estate+0.71%
- Energy+0.71%
- Basic Materials+0.12%
- Communication Services-0.51%
- Financial Services-0.55%
- Consumer Cyclical-0.63%
- Consumer Defensive-1.61%
Top industries (issuer's industry highlighted)
- Drug Manufacturers - General+1.39%
- Broadcasting+6.89%
- Oil & Gas Energy+4.23%
- Computer Hardware+4.09%
- Engineering & Construction+3.86%
- Software - Infrastructure+3.76%
- Financial - Capital Markets+3.44%
- Beverages - Non-Alcoholic-3.42%
- Semiconductors+3.32%
- Oil & Gas Drilling+3.28%
- Medical - Healthcare Information Services-3.05%
- Telecommunications Services-3.05%
Fair value
Football field →Weighted blend
—
— vs spot
Recommendation
n/a
0 of 0 methods
Method spread
0bull0bear
±5% threshold
Analyst PT consensus: $141.00 (-4.99%)
Total assets
—
Total debt
—
Cash & equiv
—
Operating CF
—
Free cash flow
—
Buybacks
—
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 yearsglobenewswire.com·Jun 04, 2026
- Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 yearsglobenewswire.com·Jun 04, 2026
- Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patientsglobenewswire.com·Jun 03, 2026
- Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patientsglobenewswire.com·Jun 03, 2026
- Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilitiesglobenewswire.com·May 07, 2026
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|